ArticleAnnals of medicine and surgery (2012)2025
Tafasitamab (MOR208) in relapsed or refractory follicular lymphoma: a promising frontier in targeted immunotherapy.
Muhammad Ahmad et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.